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The recent papers in th e J efferson J ournal of Psychiat ry by Drs. Levin
("Bulimia as a Masturbatory Equivalent, " July, 1985) a nd Wilson ("A Discussion
of 'Bulim ia as a Masturbatory Equivalent' ," Winter, 1986) contai n a numbe r of
th eories and recommendations abou t th e etio logy and treatmen t of b ulimi a
whi ch should be add ressed. In large measure , both papers present a d ynamic
view of this disorder. However , psych odynamic fo rm u lat ions are but one of
many theories put forward to exp lain this di sorder. Other theories of etiology
include notions that bulimia ar ises from cu ltu ra l fac tors and an increased
atten tio n to body image , from di sorders with in th e fami ly as a whole , or from
assorted behavioral fac to rs wh ich somehow reinforce binge-eati ng and purg-
mg.
One way to evaluat e a theory o f e tio logy is to as k wh ethe r t reatme nts based
upon a given theory benefit individuals with th e disorde r in question . Fo r
e xam ple , it would be of interest to know what evidence exists that individ ua l
psychotherapy is superior to group psychotherapy for th e treatment of bul im ia .
Similarly it is important to know what e mp ir ica l data underlie th ese theories. In
th e case of bulimia, as noted above , th ere are a host o f ideas about wha t causes
the di sorder. And whil e a review of this literature is beyond th e scope of this
paper, at this time th ere is no systematic, controlled, non-an ecdot al evidence
that psych odynamic, behavioral , o r cultura l factors a lone ca n lead to bul imia
(1,2) .
In terms of treatment, we have a sim ilar situa t ion, where co ntro lled st udies
of individual psychotherapy, group th erapy, and behavior th erapy are a lso
lacking. There are numerous uncontrolled reports of the efficacy of th ese
modal ities in bulimic pati ents, but it is important to note wh y co ntro lled studies
are important in assessing treatments of this disorder. First , bulimia may remit
sponta ne ous ly ( I), so that a placebo group is needed to evalua te if a given
th erapy is e ffect ive . Second, bulimic pati ents ma y have a mel iora tio n of symp-
toms in str uc tured se tt ings. In assessing th e fir st 40 consecutive inpatients
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admitted to the Fair Oaks Hospital Eating Disorders program, 33 had complete
cessation of binging within the first 10 da ys. Such a response is misl eading . At
the end of two weeks (before treatment is completed) nearly two-th irds of the 33
"responders" will binge and purge on their first pass, and nearly all of the 33
"responders" will report urges to binge during the first two weeks. T his kind of
phenomenon points out the need for a control group, as wel l as follow-up
information, before a given treatment can be sa id to be effecti ve.
Given the prevalence of bulimia, there are relatively few studies of psycho-
logical and group treatments. One difficulty often cited in design in g studies is
that response to therapy cannot be assessed in a systematic manner. In bulimia,
this is not the case. Bulimic patients have a number of overt sym pto ms which can
be followed readily, such as the number of binge and purge ep isodes each day,
severity of binge and purge urges, and sever ity of depression . T hus , there seems
little reason why studies of therapeutic efficacy of various modalities could not
be undertaken . Yet data supporting the use of many popular th erapies are scanty
at best. There are at this time no contro lled studies of individual psychotherapy
in bulimia beyond uncontrolled case ser ies . Cognitive behavio ral th erapy has
been reported successful in two uncontrolled studies (3 ,4) , wh ereas th erapy has
been reported useful in several uncontrolled reports (5-9).
We are not advocating that individuals with bulimia be deprived of group or
individual therapy. Rather, we are pointing out that at th is time th ere is litt le to
commend one talking therapy from another. Recommendations for group and
individual therapy should be made on an individual basis , rather than on the
basis of diagnosis alone. In conjunction with such treatment, however , we must
now address the use of a different therapeutic technique which appears applica-
ble to this diagnostic category as a whole-the use of an tidepressant med ica-
tion.
The rationale for the use ofantidepressants in bulimia co mes from th e body
of evidence linking bulimia and anorexia nervosa to affective di sorders. T his
evidence stems from three lines of research: studies of phenomenol ogy, family
history, and biological tests. Studies of phenomenology have examined groups
of bulimic patients seeking treatment for their eating disorder. Su ch studies
have consistently reported that bulimic patients have an increased life time
prevalence of major depression and bipolar disorder, and that in up to 50
percent of cases the affective disorder antedates the onset of th e eating di sorder
(10-12) . Studies of family history also suggest a biological link between affect ive
disorders and bulimia, in that most but not all groups have reported an increased
incidence of affective disorders in the families of patients with bulimia (13- 15).
The third line of evidence linking eating disorders to affecti ve di sorders
arises from studies of the dexamethasone suppression test (DST) and th yrotro-
pin releasing hormone stimulation test (TRHST). Both the DST (14 ,16 ,17) and
TRHST (14) yield positive results in bulimia at rates comparab le to those
observed among individuals with depression. These results should be inter-
preted with caution, since metabolic stresses attr ibu tab le to binging, purging,
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and weight loss could produce false positive results (18). However, studies of
inpatient bulimics have shown that the rate of dexamethasone non-suppresio n is
not affected by hospitalization , even after binging and purging are co ntrolled
through milieu treatment (16,19).
The evidence summarized above suggests a biologica l link between
bulimia and the affective disorders. It should be noted that th ere a re aspects of
th e eat ing disorders not explained by this linkage, suc h as th e relat ionsh ip of
eating disorders and substance abuse (20). However, th e affecti ve model of
eating disorders has led to an important treatment of bulimia , th e use of
antidepressant medication.
Numerous open-studies of antidepressants in bulimia have appeared in the
literature since 1977 (1,2) , describing the use of heterocyclic antidepressants
and monoamine oxidase inhibitors (MAOI's). Since th en , five pla cebo-
controlled, double-blind studies of heterocyclic antidepressants or MAOI's have
been completed (21-25). One study using low dosages of mianserin had negative
resu lts (21), and one study using amitriptyline had weakly positive results (22) .
Both studies appeared to suffer from the use of inadequate dosages of antide-
pressant. The other three studies of antidepressants reported strongly positive
findings. Pope et al. (23) observed a 70 percent reduction o f b inge-eat ing in
patients taking imipramine in dosages up to 200 mg each day, as compared to
vir tua lly no change in a placebo-control group. Significant reductions in depres-
sion , food preoccupation , and subjective global improvement were also noted .
Walsh et al. had similarly positive re sults using phenelzin e (23), as d id Hugh es et
al. using desipramine (24). The study by Hughes and colleagues was of particu lar
interest because ·they selected bulimic patients who did not d isplay major
depression. Despite this fact , Hughes' group found that 15 (68 %) of 22 subjects
experienced a remission of th eir bulimic sympto ms within ten wee ks. Another
important finding of the Hughes study was that pla sma levels of desip ram ine
comparable to those required in depression were required for res ponse, and that
dosages up to 350 mg of desipramine were required to obtain adequa te serum
levels (125-275 ug /ml in their laboratory).
Overall, a growing body of evidence supports th e use of ant idepressant
medication in the treatment of bulimia, whether or not th e patient suffers from
conco mitant major depression. Follow-up data from th e study of Pope e t al.
further support the utility of antidepressants (26). After one to two yea rs on
medication, 50 percent of patients were free of bulimic symptoms, 45 percent
had a greater than 50 percent reduction of symptoms, and only one pa tient , who
had discontinued medication , was unchanged. These promising data are tem-
pered by the fact that complicated pharmacologic treatments were requi red in
so me cases in order to achieve maximal results. Nevertheless, a majority of these
patients were able to return to full function , and did so without th e aid of other
ancillary therapies.
A number of caveats should be rai sed at this point. First, agents o ther than
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antidepressants have been useful in bulimia , including lithium (27), and methyl-
amphetamine (28) . Naltrexone has a lso been reported to be of use in these
patients (29), but only on an open-label basis. In ge neral, treatment with
th ymoleptics must be syste matic and care fu l utilizing medication in adequate
dosages for adequate pe riods of time , ca refu lly monitoring serum levels (30).
Second, medication does not interfere with psych otherapy. If anything the
co gn itive improvement whi ch patients exper ience when depression and food
preoccupation lessen make th em more amenable to th erapy.
Third, the notion th at patients should be allowed to " exper ience" thei r
eat ing disorder in order to achieve insight should be co ns idered as archaic and
cruel as notions that antidepressants should be withheld from depressed individ-
ual s for like reasons. Such an approach is also medicall y dan gerous, in light of
the ph ysical damage whi ch may attend constant binging and purging . The role
of treatment is to hasten recovery, and antidepressant th erapy ca n help in this
regard.
Finally, clinicians often misinterpret the use of ant idepressants as a de facto
statement against the use of psychotherapy. This is untrue. Many if not most
patients with bulimia will have individual and family problems whic h require
individual , group, and family psychotherapy. In our own treatment p rogram ,
patients are engaged in all of th ese th erapies, in addition to mi lieu, nutritional,
and exe rc ise therapy. In treating the whole patient, one needs to address
biological as well as psychological needs. In so doing , the use of thymoleptics
plays an important role. Given th e evidence fo r th e efficacy of antidepressants in
bulimia , th ere is little rea son to withhold th em from pat ient s with this disorder.
[ Ed.: For Dr. Wilson' s reply, see the Letters to the Ed itor section.)
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